IONP-LPrA2

IONP-LPrA2 is a nanoparticle-conjugated therapeutic candidate designed to inhibit leptin signaling in the context of pancreatic cancer. It comprises the leptin peptide antagonist LPrA2 covalently attached to iron-oxide nanoparticles (IONPs). By antagonizing the leptin receptor (OB-R), IONP-LPrA2 disrupts the leptin-Notch crosstalk axis, which is implicated in the expansion of pancreatic cancer stem cells (PCSCs), tumor aggressiveness, and resistance to chemotherapy (e.g., gemcitabine and 5-FU). Preclinical studies in mouse xenograft models have demonstrated that IONP-LPrA2 can delay tumor onset and reduce tumor growth without affecting food intake or body weight, suggesting its potential as a targeted therapy for obese patients with pancreatic cancer.

Other names

iron-oxide nanoparticle-bound LPrA2LPrA2-bound iron-oxide nanoparticlesLPrA-2-bound iron-oxide nanoparticlesLPrA 2-bound iron-oxide nanoparticles